CERo Therapeutics Adds UC Davis as Site for Phase 1 CER-1236 Trial in Blood Cancers
Bitget2026/10/26 21:22- CERo Therapeutics activated UC Davis as a site for its ongoing Phase 1 CERTAIN-T trial of CER-1236 in blood cancers.
- UC Davis also manufactures CER-1236, potentially expanding recruitment capacity while shortening the time between manufacturing and patient infusion.
- Previously reported findings covered six patients; a June 2026 update showed no severe treatment-related adverse events during the initial safety assessment.
- Preliminary observations indicated clinical improvement in two patients, but formal assessments remain ongoing; definitive safety or efficacy conclusions cannot yet be drawn.
- The trial protocol now includes myelodysplastic syndromes and myelofibrosis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Despite a 16% drop in sales, profit remains stable! Porsche (POAHY.US) maintains its earnings, with the 911 as a key support
Despite another significant decline in car sales, the profitability of the German luxury carmaker Porsche remains stable. The demand for high-end models such as the 911 and its expensive derivative models has helped the company cushion the impact of weak performance in the Chinese market.
Equities: AI optimism lifts global stocks and chipmakers – Danske Bank
USD/JPY Price Forecast: Strives to return above 20-day EMA
Parkinson's disease therapy developer Aspen Neuroscience (ASPE.US) sets IPO price at $15-17 per share, aiming to raise $150 million
Aspen Neuroscience has announced its IPO terms.
Crypto prices
More
